Sign In
Buy OMER
$10.16
-0.1000 (-0.97%)
At Close: Jun 03, 2026
Could This Obscure Biotech Stock Make You a Fortune?
10:27am, Sunday, 26'th Jul 2020
Two major catalysts on the horizon could send Omeros' stock soaring. What should investors think?
The Play On Omeros
03:48pm, Friday, 17'th Jul 2020
Today, we revisit Omeros. The company has two potential catalysts on the near term horizon and the stock is a good covered call candidate.
Omeros'(NASDAQ:OMER) Share Price Is Down 35% Over The Past Three Years.
07:06pm, Wednesday, 15'th Jul 2020
Many investors define successful investing as beating the market average over the long term. But its virtually certain...
Hedge Funds Are Buying Omeros Corporation (OMER)
08:27pm, Wednesday, 24'th Jun 2020
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investmen
ROCKVILLE, MD / ACCESSWIRE / June 22, 2020 / The American Kidney Fund (AKF) today announced a new corporate membership program open to institutional partners that support AKF's core mission of fi
Market Segmentation & Coverage: This research report categorizes the Cataract Surgery Devices to forecast the revenues and analyze the trends in each of the following sub-markets:
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at Annual European Hematology Association Congress
12:30pm, Friday, 12'th Jun 2020
Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSC
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at Annual European Hematology Association Congress
12:00am, Friday, 12'th Jun 2020
Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell tra
Omeros’ Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress
12:45pm, Thursday, 11'th Jun 2020
Omeros Corporation (Nasdaq: OMER): The results of Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will b
Edited Transcript of OMER earnings conference call or presentation 11-May-20 8:30pm GMT
06:28pm, Monday, 08'th Jun 2020
Q1 2020 Omeros Corp Earnings Call
Omeros Gets Technical Rating Upgrade, Relative Strength Line Moves Up To 75
10:45pm, Tuesday, 26'th May 2020
On Tuesday, Omeros received a positive adjustment to its Relative Strength (RS) Rating, from 67 to 75. Over 100 years of market history shows that the market's biggest winners tend to have an RS Rati
The global eyewear market size is expected to reach USD 178.95 Billion by 2026; owing to increasing cases of deteriorating eye health and trendsetting launch of
Consonance Capital Management LP Buys Akebia Therapeutics Inc, Sarepta Therapeutics Inc, ...
12:00am, Friday, 15'th May 2020Omeros: Some Concerns Remain... As Do Opportunities
02:05pm, Thursday, 14'th May 2020
Today, we circle back on Omeros whose two main assets are Omidria and OMS721. The company's quarterly report had some Covid19 impacts and two potential large ca
